JP2024522770A - 標識化ステップ中に低い含水量を有する、［１８ｆ］放射性標識された化合物を調製するための方法 - Google Patents

標識化ステップ中に低い含水量を有する、［１８ｆ］放射性標識された化合物を調製するための方法 Download PDF

Info

Publication number
JP2024522770A
JP2024522770A JP2023577714A JP2023577714A JP2024522770A JP 2024522770 A JP2024522770 A JP 2024522770A JP 2023577714 A JP2023577714 A JP 2023577714A JP 2023577714 A JP2023577714 A JP 2023577714A JP 2024522770 A JP2024522770 A JP 2024522770A
Authority
JP
Japan
Prior art keywords
ppm
water content
fluoride
drying
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023577714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522770A5 (enExample
Inventor
エンゲル，トーグリム
マクロビー，グレイム
クラーク，アラン
グリッグ，ジュリアン
アハメド カーン，イムティアズ
ウィケネ，クリスチャン
シェールズ，ジョナサン
ジャクソン，アレクサンダー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2024522770A publication Critical patent/JP2024522770A/ja
Publication of JP2024522770A5 publication Critical patent/JP2024522770A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023577714A 2021-06-16 2022-06-16 標識化ステップ中に低い含水量を有する、［１８ｆ］放射性標識された化合物を調製するための方法 Pending JP2024522770A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108605.3 2021-06-16
GBGB2108605.3A GB202108605D0 (en) 2021-06-16 2021-06-16 Effect of water content
PCT/EP2022/066483 WO2022263594A1 (en) 2021-06-16 2022-06-16 Method for preparing an [18f] radiolabelled compound with low water content during labelling step

Publications (2)

Publication Number Publication Date
JP2024522770A true JP2024522770A (ja) 2024-06-21
JP2024522770A5 JP2024522770A5 (enExample) 2025-06-23

Family

ID=76954450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023577714A Pending JP2024522770A (ja) 2021-06-16 2022-06-16 標識化ステップ中に低い含水量を有する、［１８ｆ］放射性標識された化合物を調製するための方法

Country Status (12)

Country Link
US (2) US20240366808A1 (enExample)
EP (1) EP4355715A1 (enExample)
JP (1) JP2024522770A (enExample)
KR (1) KR20240021888A (enExample)
CN (1) CN117500773A (enExample)
AU (1) AU2022294052A1 (enExample)
BR (1) BR112023026514A2 (enExample)
CA (1) CA3223802A1 (enExample)
GB (1) GB202108605D0 (enExample)
IL (1) IL308917A (enExample)
MX (1) MX2023015076A (enExample)
WO (1) WO2022263594A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520527D0 (en) 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
EP2880005B1 (en) * 2012-07-30 2016-05-25 Technical University of Denmark Radiofluorination method
CN107207379B (zh) * 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3423113B1 (en) * 2016-02-29 2020-09-02 Oncodesign S.A. Radiolabeled macrocyclic egfr inhibitor
US11583596B2 (en) * 2017-09-26 2023-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Radiolabeled Darapladib and analogs thereof and their use as imaging compounds

Also Published As

Publication number Publication date
KR20240021888A (ko) 2024-02-19
US20240366808A1 (en) 2024-11-07
AU2022294052A1 (en) 2023-12-14
CN117500773A (zh) 2024-02-02
WO2022263594A1 (en) 2022-12-22
IL308917A (en) 2024-01-01
MX2023015076A (es) 2024-01-18
CA3223802A1 (en) 2022-12-22
BR112023026514A2 (pt) 2024-03-05
GB202108605D0 (en) 2021-07-28
EP4355715A1 (en) 2024-04-24
US20250312494A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
EP2419096B1 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
JP7657759B2 (ja) 新規製剤及び合成方法
JP5258583B2 (ja) 放射性画像診断剤の製造方法
KR20190119673A (ko) 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물
US20250312494A1 (en) Method for preparing an [18f] radiolabelled compound with low water content during labelling step
US7018614B2 (en) Stabilization of radiopharmaceuticals labeled with 18-F
EP3757101A1 (en) Process for producing fluorinated compounds using an alcohol solvent having an unsaturated hydrocarbon group
JP6446268B2 (ja) クエン酸緩衝液中の１８ｆ−フルシクロビン組成物
KR101842989B1 (ko) 카보닐기를 갖는 알코올 용매를 이용한 플루오르화 화합물의 제조방법
Wadsak et al. 18F fluoroethylations: different strategies for the rapid translation of 11C-methylated radiotracers
US20240350683A1 (en) Preparation of a ph-adjusted ascorbic acid solution
JP7424574B2 (ja) 放射性フッ素標識化合物の製造方法及び放射性医薬組成物の製造方法
JP5106118B2 (ja) 放射性フッ素標識有機化合物の製造方法
WO2025114063A1 (en) Stabilized method for 18f-labeling
Huang et al. A two‐centre practical evaluation of [F‐18] FDOPA production methods and comparative dosimetry estimations based on in‐vivo microPET scans
EP4559890A1 (en) Stabilized method for 18f-labeling
US10695450B2 (en) Synthesis of a radioactive agent composition
EP3536686B1 (en) Method for producing a radiopharmaceutical composition
BE1024388B1 (fr) Procede pour la preparation d'analogues de nitroimidazole a base de nucleoside radiomarques
KR101592291B1 (ko) 고순도 및 고비방사능의 [18f]플루오로-l-도파의 제조 방법
JP2012246255A (ja) １１ｃ標識アミノ酸類似体の製造方法および核医学画像診断薬
Vallabhajosula Chemistry of Radiohalogens (F, Br, and I)
HK1167344B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250613

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250613